IZOTROPIC CORP - IZOZF STOCK NEWS

Welcome to our dedicated page for IZOTROPIC news (Ticker: IZOZF), a resource for investors and traders seeking the latest updates and insights on IZOTROPIC stock.

Izotropic Corporation is a medical device company specializing in IzoView, a CT imaging system used for non-invasive tissue characterization, particularly in breast imaging. The company recently completed a pre-submission application to the FDA for market clearance of IzoView as a Class II device through a 510(k) pre-market notification submission. Izotropic is also focusing on collaborations with hospitals to generate clinical data supporting new products and regulatory submissions.

08/23/2024 09:00 AM

News

Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU

Rhea-AI Summary

Izotropic (CSE: IZO) (OTCQB: IZOZF) announces plans to launch IzoView, a breast CT imaging system, as a diagnostic device for patients with dense breast tissue in the U.S. and EU. The company is pursuing a Pre-Market Authorization (PMA) clinical study in the U.S., estimated to cost $3.5M USD and involve 400 patients. The study aims to prove the superiority of Digital Breast Tomosynthesis (DBT) combined with Contrast-Enhanced Breast CT over DBT alone for breast cancer detection in women with dense breasts.

Izotropic is also seeking CE Mark approval in the EU, which may result in earlier commercialization. The company's strategy focuses on patients with BI-RADS C and D breast density classifications, addressing a significant market as nearly half of U.S. women aged 40+ have dense breasts, which increases breast cancer risk.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.54%

Tags

01/30/2024 08:00 AM

News

Izotropic Receives Response From U.S. FDA

Rhea-AI Summary

Izotropic Corporation, a medical device company, announces that it has received a response from the U.S. FDA regarding its pre-submission seeking guidance on a Class II 510(k) pathway for its CT imaging system. The FDA's mammogram and ultrasound team has responded with additional questions, and Izotropic's management, regulatory, and engineering teams will promptly respond and report the outcomes. As of the announcement date, there has been no material change to the Company's regulatory plans and no definitive decision provided by the FDA.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

12.75%

Tags

01/08/2024 08:00 AM

News

Izotropic Provides Regulatory and Operational Updates

Rhea-AI Summary

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) provides an update on its regulatory status with the U.S. Food and Drug Administration and operational activities, including FDA pre-submission meeting, ongoing correspondence, and business development discussions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.91%

Tags

11/01/2023 08:00 AM

News

Izotropic Completes Pre-Submission Meeting with U.S. FDA

Rhea-AI Summary

Izotropic Corporation, a medical device company, completed a pre-submission meeting with the U.S. FDA to discuss its application for market authorization. The meeting allowed Izotropic to clarify its regulatory strategy and the FDA appeared open to the company's new market clearance direction.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.14%

Tags

09/27/2023 09:00 AM

News

Izotropic Confirms FDA Pre-Submission Meeting Date

Rhea-AI Summary

Izotropic Corporation confirms pre-submission meeting with FDA for its CT imaging system, IzoView, on October 25, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.33%

Tags

09/06/2023 08:00 AM

News

Izotropic Files Class II Pre-Submission with FDA & Releases Details on Predicate Devices

Rhea-AI Summary

Izotropic Corporation completes pre-submission application to FDA for market clearance of IzoView CT Imaging System as a Class II device. Plans to use pre-existing data for 510(k)-submission and aims for market clearance in the second half of 2024. Intends to secure collaborations with hospitals for generating clinical data. Switching to Class II pathway due to lower costs and shorter timeline. Selects CurveBeam HiRise and NeuroLogica OmniTom as predicate devices. Proceeding confidently with Class II 510(k) pathway.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.44%

Tags

06/20/2023 08:00 AM

News

Izotropic Modifies Market Approval Pathway & Strategy

Rhea-AI Summary

Izotropic Corporation modifies its FDA market approval pathway for IzoView, a breast imaging system, by deferring Class III device classification and pursuing Class II regulatory clearance. The modified strategy is expected to shorten the approval timeline, save $10+ million in investment, and provide broader intended use for clinicians.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.6%

Tags

06/08/2023 08:00 AM

News

Izotropic CEO Resigns

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.94%

Tags

FAQ

What is the current stock price of IZOTROPIC (IZOZF)?

The current stock price of IZOTROPIC (IZOZF) is $0.054 as of October 15, 2024.

What is the market cap of IZOTROPIC (IZOZF)?

The market cap of IZOTROPIC (IZOZF) is approximately 2.9M.

What is Izotropic Corporation known for?

Izotropic Corporation specializes in IzoView, a CT imaging system for non-invasive tissue characterization, especially focused on breast imaging.

What recent achievement did Izotropic Corporation have?

Izotropic recently completed a pre-submission application to the FDA for market clearance of IzoView as a Class II device through a 510(k) pre-market notification submission.